A 20-Year Retrospective Analysis of Skin Cancers: Comparison of the First and Second Decades

Abstract

Objective: The incidence of skin cancer increases day by day depending on environmental factors. Developing diagnostic and pathological methods provide correct typing of skin cancers.

Method: This retrospective analysis included patients who presented to and were scheduled for treatment at Sivas Cumhuriyet University Plastic Reconstructive and Aesthetic Surgery Clinic between January 1, 2000 and December 31, 2019 due to skin cancer and carcinoma in situ. The results were divided two groups as first ten years and second ten years. The groups were compared among themself in terms of cancer type, age, gender and localization

Results: 619 cases' 652 skin cancer and in situ carcinoma results were detected. When the groups were compared in terms of tumor types detected, there was a significant increase in MM, Bowen's disease, and rare NMSC subtypes other than SCC and BCC in the second decade (p<0.001). Comparison of NMSC and MSC rates between the groups showed that the incidence of MSC had increased significantly from 5.2% to 10% in the past 10 years (p<0,05)

Conclusion: Rare Non-melanocytic skin cancer group includes many types of carcinoma, there are various treatment protocols. Furthermore, many members of this group are known to be more aggressive than Basal cell carcinoma and squamous cell carcinoma. There are no consesnsus especially for approaches targeting lymph nodes. Closely following is necessary for early detection of recurrences and metastases.

Keywords

• Skin cancer
• Non-melanocytic skin cancer
• melanocytic skin cancer

Cilt Kanserlerinin 20 Yıllık Retrospektif Analizi: Birinci 10 Yıl İle İkinci 10 Yılın Karşılaştırılması

Abstract

Amaç: Çevresel faktörlere bağlı olarak cilt kanserlerinin insidansı gün geçtikçe artmaktadır. Gelişen tanısal ve patolojik metotlar kanserlerin daha doğru tiplendirilmesine yardımcı olmaktadır.

Yöntem: Çalışmamızda cilt kanserleri ve in situ karsinom nedeniyle 1 Ocak 2000-31 Aralık 2019 tarihleri arasında kliniğimizde tedavi amacıyla başvuran ve tedavisi planlanan hastalar dahil edildi. Hastalar ilk on yıl ikinci on yıl olarak iki gruba ayrıldı. Gruplar; kanser tipi, yaş, cinsiyet ve lokalizasyon açısından karşılaştırıldı.

Bulgular: 619 vakaya ait 652 cilt kanseri ve insitu karsinom tespit edildi. Gruplar karşılaştırıldığında ikinci on yılda malign melanoma, Bowen hastalığında ve nadir gözlenen Non Melanositik Cilt Kanseri (NMCK)’nin alt tiplerinde anlamlı bir artış olduğu gözlendi (p<0,001). NMCK ve Melanositik Cilt Kanseri (MCK) karşılaştırıldığında MCK insidansının son 10 yılda %5.2 den % 10 a yükselmesi istatistiksel açıdan anlamlı idi (p<0,05).

Sonuç: Nadir gözlenen NMCK’ler çeşitli tedavi protokolleri olan pek çok karsinom tiplerini içermektedir. Ayrıca bu grubun pek çok üyesinin Bazal Hücreli Kanser ve Skuamöz Hücreli Kanserden daha agresif seyrettikleri bilinmektedir. Özellikle lenf nodlarına karşı yaklaşım hakkında ortak bir konsensüs bulunmamaktadır. Rekürens ve metastazların erken tespit edilebilmesi için yakın takip gereklidir.

Keywords

• Deri kanseri
• Melanositik deri kanseri
• Merkel hücreli karsinom
• Malign ekrin poroma
• Malign noduler hidradenom

References

1. 1. References 1: World Cancer Research Fund International [cited 2019 Nov 20]. Available from: https://www.wcrf.org/dietandcancer/cancer-trends/skin-cancerstatistics 2. References 2: Holm RP.Skin cancer prevention and screening. S D Med 2015; 75(7):79-81.
2. 3. References 3: Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, et al. Nonmelanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014;134(1):43-50.
3. 4. References 4: Türkiye kanser kontrol programı (2018) Halk Sağlığı Genel Müdürlüğü [cited 2019 Nov 20]. Available from: https://hsgm.saglik.gov.tr ›Ulusal_Kanser_Kontrol_ Plani_2013_2018 5. References 5: Katalinic A, Kunze U, Schafer T Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Brit J Dermatol 2003 149:1200–6 6. References 6: Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both? Ann Surg Oncol. 2019 Feb;26(2):379-385 7. References 7: Saeb-Lima M, Montante- Montes de Oca D, Albores Saavedra J. Merkel cell carcinoma with eccrine differentiation: a clinicopathologic study of 7 cases. Ann Diagn Pathol 2008;12: 410. 8. References 8: Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW et al Multimodality treatment of Merkel cell carcinoma:Case series and literature review of 1024 cases. Ann Surg Oncol. 2001 Apr;8(3):204-8. 9. References 9: Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: longterm results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996;3:446 –52
4. 10. References 10: Peter J. Allen, Wilbur B. Bowne, David P. Jaques, Murray F. Brennan, Klaus Busam, and Daniel G. Coit Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution. J Clin Oncol 2005; 23:2300-2309
5. 11. References 11: Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope 1992;102:244–9 12. References 12: Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer 1997;80:881–5.
6. 13. References 13: Victor NS, Morton B, Smith JW. Merkel cell cancer: is prophylactic lymph node dissection indicated? Am Surg 1996; 62:879–82
7. 14. References 14: Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913–23
8. 15. References 15: Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: a clinicopathologic study of 35 cases. Arch Dermatol. 1983;119(2):104-14.

9. 16. References 16: Vernekar SS, Priyadharshini Bargunam P.Malignant nodular hidradenoma-inguinal region clinically masquerading as squamous cell carcinoma: a case report. Int J Res Med Sci. 2019 Jul;7(7):2848-2852
10. 17. References 17: Stout AP, Cooley SGE. Carcinoma of sweat glands.Cancer. 1951;4 521–536.
11. 18. References 18: Souvatzidis P, Sbano P, Mandato F, Fimiani M, Castelli A. Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol. 2008 May;22(5):549-54. 19. References 19: Hall J, Kneey G, A’Hern RP, et al. Sweat-gland Tumours: A Clinical Review of Cases in One Centre Over 20 Years. Clin Oncol. 2006;18:351–359. [PubMed] [Google Scholar]
12. 20. References 20: Harari PM, Shimm DS, Bangert JL, et al. The role of radiotherapy in the treatment of malignant sweat gland neoplasms. Cancer. 1990;65:1737–17340
13. 21. References 21: Nongkynrih A,Kamboj K, Dhull A.K, Kaushal V, Miraculous response to radiotherapy in a rare case of malignant nodular hidradenoma nose J Cancer Prev Curr Res. 2018;9(3):97‒99.
14. 22. References 22: Jouary T, Kaiafa A, Lipinski P, Vergier B, Lepreux S. Metastatic hidradenocarcinoma: efficacy of capecitabine. Arch Dermatol 2006; 142: 1366–1367.
15. 23. References 23: Khalil HM, Yusuf H, Kaddour HS. Malignant eccrinehidradenoma of neck causing acute heart failure. Auris Nasus Larynx 2003;30307–310
16. 24. References 24: Chang AS, Busam MD, Kraus DK. Applicability of lymphoscintigraphy withsentinel node biopsy to eccrine carcinomaof the head and neck. Head Neck 2003;25:879–82
17. 25. References 25: Bogner PN, Fullen DR, Loew L, et al.Lymphatic mapping and sentinel lymphnode biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer 2003;97:2285–9 26. References 26: Tolland JP, Brenn T, Guldbakke KK, Schanbacher CF. Mohs micrographic surgery sentinel lymph node mapping, andestrogen receptor analysis for the treatment of malignant nodular hidradenoma. Dermatol Surg 2006; 32: 1294–1301.
18. 27. References 27: Riera-Leal L, Guevara-Gutiérrez E, Barrientos-García JG, Madrigal-Kasem R, Briseño-Rodríguez G, Tlacuilo-Parra A (2015) Eccrine porocarcinoma: epidemiologic and histopathologic characteristics. Int J Dermatol 54:580–586
19. 28. References 28: Bhat W, Akhtar S, Khotwal A, Platt AJ. Primary eccrine porocarcinoma of the finger with transit forearm and axillary metastasis. Ann Plast Surg 2011;66:344–6.
20. 29. References 29: Nazem A, Higgins S, Swift R, In G, Miller K, Wysong A, Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature Dermatol Surg 2018;44:1247–1261
21. 30. References 30: Robson A, Greene J, Ansari N, Kim B, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. AmJ Surg Pathol 2001;25:710–20.
22. 31. References 31: Sawaya JL, Khachemoune A Poroma: a review of eccrine, apocrine, and malignant forms. Int J Dermatol 2014 53:1053–1061
23. 32. References 32: Tolkachjov S, Hocker T, Camilleri M, Baum C. Treatment of porocarcinoma with Mohs micrographic surgery: the Mayo Clinic experience. Am Soc Dermatol Surg 2016;42:745–50.
24. 33. References 33: Belin E, Ezzedine K, Stanislas S et al (2011) Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol 165: 985–989
25. 34. References 34: Swanson JD Jr., Pazdur R, Sykes E: Metastatic sweat gland carcinoma: Response to 5-fluorouracil infusion. J Surg Oncol, 1989; 42(1): 69–72
26. 35. References 35: Vleugels FR, Girouard SD, Schmults CD et al: Metastatic eccrine porocarcinoma after Mohs micrographic surgery: A case report. J Clin Oncol, 2012; 30(21): e188–91
27. 36. References 36: Snow SN, Reizner GT. Eccrine porocarcinoma of the face. J Am Acad Dermatol. 1992;27(2 Pt 2):306–11.
28. 37. References 37: Avraham JB, Villines D, Maker VK et al: Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: Risk factors and trends in outcomes. J Surg Oncol, 2013; 108(1): 57–62
29. 38. References 38: Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016;42(suppl1):S24-S31. 39. References 39: Liang CA, Jambusaria-Pahlajani A, Karia PS, et al( 2014). A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014;71:781-786.
30. 40. References 40: Rutkowski, P., & Debiec-Rychter, M. (2015). Current treatment options for dermatofibrosarcoma protuberans. Expert Review of Anticancer Therapy, 15(8), 901–909
31. 41. References 41: Huis In 't Veld E, van Coevorden F, Grünhagen DJ, Smith MJ, Van Akkooi ACJ, Wouters MWJMand et al Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated? Cancer. 2019 Mar 1;125(5):735-741
32. 42. References 42: Hoesly PM, Lowe GC, Lohse CM, Brewer JD, Lehman JS. Prognostic impact of fibrosarcomatous transformation in dermatofibrosarcoma protuberans: a cohort study. J Am Acad Dermatol. 2015;72: 419-425
33. 43. References 43: Frezza AM, Botta L, Pasquali S, et al. An epidemiological insight into epithelioid sarcoma (ES): the open issue of distal-type (DES) versus proximal type (PES). Presented at the European Society of Medical Oncology Annual Meeting, Madrid, Spain, September, 2017.
34. 44. References 44: Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E et alAnthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 Sep 1;4(9):e180219.
35. 45. References 45: Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000;7:218–225.
36. 46. References 46: Gambini C, Sementa A, Rongioletti F. “Proximal-type” epithelioid sarcoma in a young girl. Pediatr Dermatol. 2004;21:117–120.
37. 47. References 47: Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma.Ann Surg Oncol. 2000;7:218–225.
38. 48. References 48: De Visscher SA, van Ginkel RJ, Wobbes T, Veth RP, Ten Heuvel SE, Suurmeijer AJ, et al Epithelioid sarcoma: Still an only surgically curable disease. Cancer. 2006 Aug 1;107(3):606-12.
39. 49. References 49: Guzzetta AA, Montgomery EA, Lyu H, et al. Epithelioid sarcoma: one institution's experience with a rare sarcoma. J Surg Res. 2012;177:116–122. 50. References 50: de Visscher SA, van Ginkel RJ, Wobbes T, et al. Epithelioid sarcoma: still an only surgically curable disease. Cancer. 2006;107:606–612.
40. 51. References 51: Sambri A, Bianchi G, Cevolani L, Donati D, Abudu A.Can radical margins improve prognosis in primary and localized epithelioid sarcoma of the extremities? J Surg Oncol. 2018 May;117(6):1204-1210 52. References 52: Alex Seal A, Tse R, Wehrli B, Hammond A Temple C. Sentinel node biopsy as an adjunct to limb salvage surgery for epithelioid sarcoma of the hand World Journal of Surgical Oncology 2005, 3:41
41. 53. References 53: Sobanko JF1, Meijer L, Nigra TP. Epithelioid sarcoma: a review and update J Clin Aesthet Dermatol. 2009 May;2(5):49-54.
42. 54. References 54: Moreno C, Jacyk W.K., Judd M.J., Requena L .Highly Aggressive Extraocular Sebaceous Carcinoma The American Journal of Dermatopathology 23(5): 450–455, 2001
43. 55. References 55: Giridhar P, Kashyap L, Mallick S, Dutt Upadhyay A, Rath GK ,Impact of surgery and adjuvant treatment on the outcome of extraocular sebaceous carcinoma: a systematic review and individual patient's data analysis of 206 cases. Int J Dermatol. 2019 Dec 18
44. 56. References 56: Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 2009; 115: 158–165.
45. 57. References 57: Ornellas AA, Frota R, Lopes da Silva LF, Dauster B, Quirino R, de Santos Schwindt AB, Pereira MR (2009) Sebaceous carcinoma of the penis. Urol Int 82:477–480.
46. 58. References 58: Sawyer AR, McGoldrick RB, Mackey S, Powell B, Pohl M (2009) Should extraocular sebaceous carcinoma be investig using sentinel node biopsy? Dermatol Surg 35:704–708
47. 59. References 59: Kibbi N, Worley B, Owen JL, Kelm RC, Bichakjian CK, Chandra S. Sebaceous carcinoma: controversies and their evidence for clinical practice. Arch Dermatol Res. 2019 Aug 30
48. 60. References 60: Kyllo R.L., Brady K.L. Hurst E.A. Sebaceous Carcinoma: Review of the Literature Dermatol Surg 2015;41:1–15
49. 61. References 61: Thornhill R. S., Scott T. Aggressive Spindle Cell Neoplasm Atlas of Mohs and Frozen Section Cutaneous Pathology Chapter 25 pp 241-242
50. 62. References 62: John AM, Singh P, Handler MZ, Lambert WC. Aggressive Mimicry in Dermatology: When a Basal or Squamous Cell Carcinoma Mimics a Spindle Cell Tumor. Skinmed. 2018 Feb 1;16(1):39-41.
51. 63. References 63: Fernandez-Flores A. Study of D2-40 immunoexpression of the spindle cell areas of a metaplastic basal cell carcinoma (sarcomatoid basal cell carcinoma). Appl Immunohistochem Mol Morphol. 2012;20:518–522.
52. 64. References 64: Harvey NT, Sinha A, Houghton DC, et al. Basal cell carcinosarcoma: A report of 4 cases and review of the literature. Am J Dermatopathol. 2014;36:483–489. 65. References 65: Bigby SM, Charlton A, Miller MV, Zwi LJ, Oliver GF. Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): Four cases with immunohistochemistry and review of the literature. J Cutan Pathol. 2005;32:141–147.
53. 66. References 66: John D, Jayalekshmi B, Mathew A S Mathew S.S Spindle Cell Squamous Cell Carcinoma with Unique Presentation in Middle Aged Indian Man: A Case Report East African Scholars J Med Sci 2019;2(12): 697-699
54. 67. References 67: Walia R1, Jain D, Mathur SR, Iyer VK. Spindle cell melanoma: a comparison of the cytomorphological features with the epithelioid variant. Acta Cytol. 2013;57:557-61.
55. 68. References 68: Shivamurthy A, Kudva R, Kudva A, Jaiprakash P Metastatic spindle cell melanoma on cytology – A diagnostic challenge Our Dermatol Online. 2019;10(2):159-162.
56. 69. References 69: Carr S, Smith C, Wernberg J. Epidemiology and Risk Factors of Melanoma. Surg Clin North Am. 2020 Feb;100(1):1-12
57. 70. References 70: Offenmueller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). Klin Padiatr. 2017 Nov;229(6):322-328.
58. 71. References 71: Omie Mills, MD, and Jane L. Messina, MD Pediatric Melanoma: A Review Cancer control J 2009; 16(3):225-233
59. 72. References 72: Downard CD, Rapkin LB, Gow KW. Melanoma in children and adolescents. Surg Oncol. 2007;16(3):215-220. 73. References 73: Paradela S, Fonseca E, Pita-Fernandez S et al. Prognostic factors for melanoma in children and adolescents: a clinicopathologic, singlecenter study of 137 Patients. Cancer 2010; 116: 4334–4344
60. 74. References 74: Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTC-MCG multicenter study on the clincopathological aspects. Int J Cancer. 1996;4:317-324.
61. 75. References 75: Erin E. Ducharme, Nanette B. Silverberg, Pediatric Malignant Melanoma: An Update on Epidemiology, Detection, and Prevention Cutis. 2009 Oct;84(4):192-8.
62. 76. References 76: Jafarian F, Powell J, Kokta V, et al. Malignant melanoma in childhood and adolescence: report of 13 cases. J Am Acad Dermatol. 2005;53:816-822.
63. 77. References 77: Tetzlaff MT, Harms PW. Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. Mod Pathol. 2020 Jan;33(Suppl 1):42-55
64. 78. References 78: Jinnah AH, Emory CL, Mai NH, Bergman S, Salih ZT. Hidradenocarcinoma presenting as soft tissue mass: Case report with cytomorphologic description, histologic correlation, and differential diagnosis. Diagn Cytopathol. 2016 May;44(5):438-41
65. 79. References 79: Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R. Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol. 2010 Jul;134(1):22-6.
66. 80. References 80: Khan SA, Ali AAA, Ferdousı, Rıyad M, Mahmud AAH. Malignant Nodular Hidradenoma: Isolated Case Report and Review of Literature Journal of Bangladesh College of Physicians and Surgeons 2016 Apr;34(2):100-103